HEPA
Income statement / Annual
Last year (2023), Hepion Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Hepion Pharmaceuticals, Inc.'s net income was -$48.93 M.
See Hepion Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$67,131.00 |
$77,461.00 |
$86,073.00 |
$34,515.00 |
$26,737.00 |
$18,787.00 |
$21,938.00 |
$0.00 |
$21,525.00 |
$16,355.00 |
| Gross Profit |
-$67,131.00 |
-$77,461.00 |
-$86,073.00 |
-$34,515.00 |
-$26,737.00 |
-$18,787.00 |
-$21,938.00 |
$0.00 |
-$21,525.00 |
-$16,355.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$35.64 M
|
$33.27 M
|
$20.40 M
|
$12.00 M
|
$3.18 M
|
$7.59 M
|
$14.33 M
|
$13.65 M
|
$15.02 M
|
$8.40 M
|
| General & Administrative
Expenses |
$9.62 M
|
$10.35 M
|
$10.01 M
|
$8.15 M
|
$4.59 M
|
$7.00 M
|
$7.28 M
|
$7.37 M
|
$5.79 M
|
$5.56 M
|
| Selling & Marketing
Expenses |
-$67,131.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$583,707.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$9.62 M
|
$10.35 M
|
$10.01 M
|
$8.15 M
|
$4.59 M
|
$7.00 M
|
$6.69 M
|
$7.37 M
|
$5.79 M
|
$5.56 M
|
| Other Expenses |
$3.19 M |
$0.00 |
$0.00 |
$0.00 |
-$179,652.00 |
-$108,942.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$48.45 M |
$43.62 M |
$30.40 M |
$20.15 M |
$7.77 M |
$14.59 M |
$21.02 M |
$21.02 M |
$20.81 M |
$13.96 M |
| Cost And Expenses |
$48.45 M |
$43.62 M |
$30.40 M |
$20.15 M |
$7.77 M |
$14.59 M |
$21.04 M |
$21.02 M |
$20.81 M |
$13.96 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
-$9,465.00 |
$10,164.00 |
$8,859.00 |
$31,229.00 |
$554,998.00 |
$339,158.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$67,131.00
|
$77,461.00
|
$86,073.00
|
$34,515.00
|
$26,737.00
|
$18,787.00
|
$21,938.00
|
$27,993.00
|
$21,525.00
|
$16,355.00
|
| EBITDA |
-$45.19 M
|
-$43.54 M
|
-$30.32 M
|
-$20.11 M
|
-$7.92 M
|
-$14.68 M
|
-$21.02 M
|
-$25.22 M
|
-$24.59 M
|
-$13.56 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$887,110.00
|
-$1.46 M
|
-$2.31 M
|
-$146,050.00
|
$379,063.00
|
$4.95 M
|
$2.13 M
|
$4.22 M
|
$3.81 M
|
-$387,898.00
|
| Income Before Tax |
-$49.34 M |
-$45.08 M |
-$32.72 M |
-$20.32 M |
-$7.95 M |
-$9.99 M |
-$18.92 M |
-$16.80 M |
-$17.00 M |
-$14.35 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$409,022.00 |
-$2.88 M |
$8,859.00 |
$30,584.00 |
-$908,682.00 |
-$536,000.00 |
-$3.90 M |
-$1.91 M |
-$3.81 M |
$387,898.00 |
| Net Income |
-$48.93 M |
-$42.20 M |
-$32.72 M |
-$20.35 M |
-$7.04 M |
-$9.45 M |
-$15.02 M |
-$14.89 M |
-$17.00 M |
-$14.35 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-12.32 |
-11.07 |
-9.31 |
-42.06 |
-68.88 |
-1027.88 |
-2173.01 |
-2861.46 |
-7035.86 |
-7388.2 |
| EPS Diluted |
-12.32 |
-11.07 |
-9.31 |
-42.06 |
-68.88 |
-1027.88 |
-2173.01 |
-2859.26 |
-7035.86 |
-7388.2 |
| Weighted Average Shares
Out |
$3.97 M
|
$3.81 M
|
$3.51 M
|
$483,891.00
|
$102,162.00
|
$9,193.00
|
$6,913.09
|
$5,204.00
|
$2,416.00
|
$1,942.00
|
| Weighted Average Shares
Out Diluted |
$3.97 M
|
$3.81 M
|
$3.51 M
|
$483,891.00
|
$102,162.00
|
$9,193.00
|
$6,913.09
|
$5,208.00
|
$2,416.00
|
$1,942.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
